Shandong Pharmaceutical announced that the company received an inquiry letter from the Shanghai Stock Exchange to review application documents for issuing shares to specific targets. The company will carry out relevant work with relevant parties in accordance with the requirements of the inquiry letter, complete responses and submit relevant documents to the Shanghai Stock Exchange within the prescribed period, and promptly fulfill the obligation to disclose information. The issue of issuing A-shares to specific targets needs to be reviewed and approved by the Shanghai Stock Exchange and registration approved by the China Securities Regulatory Commission before it can be implemented. There is uncertainty about whether it will eventually pass the review, registration, and timing.

Shandong Pharmaceutical announced that the company received an inquiry letter from the Shanghai Stock Exchange to review application documents for issuing shares to specific targets. The company will carry out relevant work with relevant parties in accordance with the requirements of the inquiry letter, complete responses and submit relevant documents to the Shanghai Stock Exchange within the prescribed period, and promptly fulfill the obligation to disclose information. The issue of issuing A-shares to specific targets needs to be reviewed and approved by the Shanghai Stock Exchange and registration approved by the China Securities Regulatory Commission before it can be implemented. There is uncertainty about whether it will eventually pass the review, registration, and timing.